Incyte secures second FDA approval for bile duct cancer drug in mutated cancer type
Incyte nabbed its second approval from federal regulators for cancer drug pemigatinib, branded as Pemazyre — as the potential for even more indications await.
The company, headed by CEO Hervé Hoppenot, put out word before the market opened on Friday that the FDA approved Pemazyre under priority review for relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. The drug, an FGFR1/2/3 inhibitor, was originally approved back in 2020 for cholangiocarcinoma, also known as bile duct cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.